Dare Bioscience (DARE) Misses Q2 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Dare Bioscience (DARE) PT Lowered to $11 at Brookline Capital Markets
August 18, 2025 3:59 PM EDTBrookline Capital Markets analyst Kemp Dolliver lowered the price target on Dare Bioscience (NASDAQ: DARE) to $11.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "Darés Q2 update was less informative than we expected. The company continues with plans to bring Sildenafil... More



